ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY)
CUSIP: 82835W108
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 98,600,500
- Total 13F shares
- 88,975,649
- Share change
- +5,012,599
- Total reported value
- $1,036,368,369
- Put/Call ratio
- 92%
- Price per share
- $11.65
- Number of holders
- 186
- Value change
- +$65,098,405
- Number of buys
- 86
- Number of sells
- 87
Quarterly Holders Quick Answers
What is CUSIP 82835W108?
CUSIP 82835W108 identifies SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 82835W108:
Top shareholders of SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| James E. Flynn |
3/4/5
13D/G
|
10%+ Owner · Deerfield Management Company, L.P. |
7.8%
from 13D/G
|
9,774,508
|
$180,437,416 | -$13,663,151 | 27 Jun 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
3/4/5
13F
|
Director, 10%+ Owner · Company |
11%
|
10,940,977
|
$111,050,917 | $0 | 29 Sep 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
8.4%
|
8,288,510
|
$83,299,526 | — | 30 Sep 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
7.6%
|
7,503,812
|
$75,413,311 | — | 30 Sep 2025 | |
| Rubric Capital Management LP |
13D/G
13F
|
Company |
6.3%
|
6,200,000
|
$70,556,000 | $0 | 31 Dec 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
5.1%
|
5,013,000
|
$58,401,450 | $0 | 31 Dec 2025 | |
| Pratik Shah |
3/4/5
|
Director |
—
mixed-class rows
|
4,504,554
mixed-class rows
|
$44,969,267 | — | 12 Nov 2025 | |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
|
Company |
4.1%
|
4,012,903
|
$40,329,675 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
3,500,303
|
$35,178,046 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
3.1%
|
3,097,022
|
$31,125,071 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.9%
|
2,895,256
|
$29,097,323 | — | 30 Sep 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
2.7%
|
2,642,111
|
$26,553,216 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
2.4%
|
2,398,012
|
$24,100,021 | — | 30 Sep 2025 | |
| Casdin Capital, LLC |
13F
|
Company |
1.6%
|
1,600,000
|
$16,080,000 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.6%
|
1,586,033
|
$15,939,632 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
1,505,617
|
$15,134,147 | — | 30 Sep 2025 | |
| Southpoint Capital Advisors LP |
13F
|
Company |
1.5%
|
1,500,000
|
$15,075,000 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
1,325,739
|
$13,323,677 | — | 30 Sep 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.3%
|
1,303,399
|
$13,099,160 | — | 30 Sep 2025 | |
| BAMCO INC /NY/ |
13F
|
Company |
1.3%
|
1,268,532
|
$12,748,747 | — | 30 Sep 2025 | |
| Janney Montgomery Scott LLC |
13F
|
Company |
1.2%
|
1,213,020
|
$12,191,000 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1%
|
1,034,798
|
$10,399,720 | — | 30 Sep 2025 | |
| Eversept Partners, LP |
13F
|
Company |
0.99%
|
976,511
|
$9,813,936 | — | 30 Sep 2025 | |
| LEVIN CAPITAL STRATEGIES, L.P. |
13F
|
Company |
0.78%
|
764,294
|
$7,681,155 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.77%
|
756,347
|
$7,601,289 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
0.75%
|
742,508
|
$7,462,205 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.71%
|
700,414
|
$7,039,160 | — | 30 Sep 2025 | |
| Nextech Invest, Ltd. |
13F
|
Company |
0.67%
|
660,703
|
$6,640,065 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.67%
|
659,886
|
$6,631,855 | — | 30 Sep 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.64%
|
631,720
|
$6,348,786 | — | 30 Sep 2025 | |
| K2 PRINCIPAL FUND, L.P. |
13F
|
Company |
0.63%
|
621,807
|
$6,249,160 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.54%
|
531,503
|
$5,341,605 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.53%
|
520,758
|
$5,233,618 | — | 30 Sep 2025 | |
| CenterBook Partners LP |
13F
|
Company |
0.52%
|
512,367
|
$5,149,288 | — | 30 Sep 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.4%
|
390,092
|
$3,920,425 | — | 30 Sep 2025 | |
| Empire Life Investments Inc. |
13F
|
Company |
0.36%
|
355,686
|
$3,574,644 | — | 30 Sep 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.36%
|
352,943
|
$3,547,077 | — | 30 Sep 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.34%
|
335,148
|
$3,368,237 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.28%
|
272,026
|
$2,733,860 | — | 30 Sep 2025 | |
| Laura Shawver |
3/4/5
|
Director |
—
mixed-class rows
|
240,346
mixed-class rows
|
$2,587,466 | — | 25 Jun 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.25%
|
246,170
|
$2,474,009 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.25%
|
242,037
|
$2,432,472 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.23%
|
228,569
|
$2,297,118 | — | 30 Sep 2025 | |
| Lisanti Capital Growth, LLC |
13F
|
Company |
0.21%
|
211,189
|
$2,122,449 | — | 30 Sep 2025 | |
| FAS Wealth Partners, Inc. |
13F
|
Company |
0.2%
|
200,620
|
$2,016,231 | — | 30 Sep 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.2%
|
199,153
|
$2,001,488 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.2%
|
197,320
|
$1,983,067 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.19%
|
186,726
|
$1,818,396 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.18%
|
178,148
|
$1,790,387 | — | 30 Sep 2025 | |
| WEXFORD CAPITAL LP |
13F
|
Company |
0.17%
|
168,238
|
$1,690,790 | — | 30 Sep 2025 |
Institutional Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q4 2025
As of 31 Dec 2025,
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) was held by
186 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
88,975,649 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, DEERFIELD MANAGEMENT COMPANY, L.P., Rubric Capital Management LP, BlackRock, Inc., SR One Capital Management, LP, Aberdeen Group plc, VANGUARD GROUP INC, STATE STREET CORP, and MILLENNIUM MANAGEMENT LLC.
This page lists
186
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
187
Q4 2025 holders
186
Holder diff
-1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.